

# Giovanna Malara

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/579321/publications.pdf>

Version: 2024-02-01

50  
papers

848  
citations

471509

17  
h-index

526287

27  
g-index

52  
all docs

52  
docs citations

52  
times ranked

1276  
citing authors

#	ARTICLE	IF	CITATIONS
1	A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1146-1149.	2.2	19
2	Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study. <i>Archives of Dermatological Research</i> , 2022, 314, 593-603.	1.9	8
3	Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1292-1299.	2.4	23
4	Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2021, 32, 507-513.	2.2	67
5	Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 958-964.	2.4	66
6	Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00422.	1.3	12
7	Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis. <i>European Journal of Dermatology</i> , 2021, 31, 3-16.	0.6	10
8	Dimethyl fumarate titration for the systemic treatment of moderate-to-severe plaque psoriasis. <i>Drugs in Context</i> , 2021, 10, 1-8.	2.2	5
9	Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations. <i>Dermatology and Therapy</i> , 2021, 11, 235-252.	3.0	34
10	Effectiveness of Apremilast in Real Life in Patients with Psoriasis: A Longitudinal Study. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00545.	1.3	3
11	Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 2551-2562.	1.8	3
12	Real-world effectiveness and safety of Guselkumab for the treatment of psoriasis: a 6-month prospective study in a series of psoriatic patients. <i>European Review for Medical and Pharmacological Sciences</i> , 2021, 25, 406-412.	0.7	9
13	A rare skin infection in atopic dermatitis: A case report. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 2945-2947.	0.5	1
14	Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis. <i>PLoS ONE</i> , 2020, 15, e0237267.	2.5	19
15	Consensus on the place in therapy of TNF inhibitors in the treatment of patients with chronic plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e470-e472.	2.4	6
16	Long-term efficacy and safety of apremilast in psoriatic arthritis: Focus on skin manifestations and special populations. <i>Dermatologic Therapy</i> , 2020, 33, e13440.	1.7	13
17	TNF inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 591-598.	3.0	18
18	Italian guidelines for therapy of atopic dermatitis—Adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis). <i>Dermatologic Therapy</i> , 2019, 32, e13121.	1.7	36

#	ARTICLE	IF	CITATIONS
19	Improving the disease awareness: how a communication campaign brings hidradenitis suppurativa to the light. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 7-9.	2.4	1
20	Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study. <i>British Journal of Dermatology</i> , 2019, 181, 413-414.	1.5	21
21	Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. <i>British Journal of Dermatology</i> , 2019, 180, 1547-1548.	1.5	30
22	HIDRADisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 766-773.	2.4	23
23	Rapid improvement of nail matrix psoriasis with apremilast: clinical and ultrasonographic assessment. <i>Clinical and Experimental Dermatology</i> , 2018, 43, 606-607.	1.3	6
24	Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. <i>British Journal of Dermatology</i> , 2018, 179, 1072-1080.	1.5	44
25	Consensus on the management of patients with psoriatic arthritis in a dermatology setting. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 515-528.	2.4	15
26	Is apremilast a promising treatment for psoriasis and psoriatic arthritis?. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, AB171.	1.2	0
27	HLA-Cw6 allele and efficacy of secukinumab. <i>British Journal of Dermatology</i> , 2018, 179, e207-e207.	1.5	0
28	HLA-Cw6 ç%ä½ãÿàâ'Çèèé†â•æŠ—çš,,ç—æ•. <i>British Journal of Dermatology</i> , 2018, 179, e221-e221.	1.5	0
29	Chronic spontaneous urticaria treated with omalizumab: report of two cases. <i>Journal of Dermatological Treatment</i> , 2018, 29, 3-5.	2.2	2
30	Effectiveness End Points in Real-World Studies on Biological Therapies in Psoriasis: Systematic Review with Focus on Drug Survival. <i>Dermatology</i> , 2018, 234, 1-12.	2.1	22
31	An Italian multicentre study on adult atopic dermatitis: persistent versus adult-onset disease. <i>Archives of Dermatological Research</i> , 2017, 309, 443-452.	1.9	56
32	Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study. <i>British Journal of Dermatology</i> , 2017, 176, 1195-1203.	1.5	37
33	Italian expert consensus for the management of actinic keratosis in immunocompetent patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1077-1084.	2.4	41
34	IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis. <i>Dermatology</i> , 2016, 232, 230-236.	2.1	44
35	Omalizumab for the treatment of chronic spontaneous urticaria in clinical practice. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 117, 703-707.	1.0	14
36	MANAGEMENT OF PSORIATIC ARTHRITIS: SHOULD THE INTERACTION BETWEEN DERMATOLOGISTS AND RHEUMATOLOGISTS IN CLINICAL PRACTICE BE INTENSIFIED?. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2015, 29, 547-61.	0.7	6

#	ARTICLE	IF	CITATIONS
37	Safe and effective approach of 4 immune-mediated inflammatory diseases with 1 biologic: Our results. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, AB211.	1.2	0
38	Undiagnosed psoriatic arthritis in some patients under ustekinumab treatment for psoriasis: Radiologic evolutions of joints involved in the subsequent diagnosis of psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, AB217.	1.2	0
39	Psoriasis rupioides, an uncommon form of a very common disease: A case report. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, AB209.	1.2	2
40	Observation of the behavior of cell-mediated immunity in psoriatic patients treated with ustekinumab: Early results. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, AB196.	1.2	0
41	Radiologic evolutions in patients suffering from psoriatic arthritis in treatment with adalimumab over 1 year. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, AB202.	1.2	0
42	Ustekinumab treatment in psoriatic patient suffering from chronic hepatitis C. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, AB206.	1.2	1
43	The psoriatic patient profile for infliximab. <i>European Review for Medical and Pharmacological Sciences</i> , 2011, 15, 1445-51.	0.7	10
44	C-Reactive Protein and Markers for Thrombophilia in Patients with Chronic Plaque Psoriasis. <i>International Journal of Immunopathology and Pharmacology</i> , 2010, 23, 1195-1202.	2.1	31
45	Lymphocutaneous Sporotrichosis in an Immunocompetent Patient: A Case Report from Extreme Southern Italy. <i>Mycopathologia</i> , 2008, 166, 159-162.	3.1	24
46	Re-Induction as a Possible Alternative Modality of Dose Escalation of Infliximab: A Prospective Evaluation in a Small Series of Psoriatic Patients. <i>International Journal of Immunopathology and Pharmacology</i> , 2007, 20, 647-650.	2.1	16
47	Photodynamic therapy of acne using methyl aminolaevulinate diluted to 4% together with low doses of red light. <i>British Journal of Dermatology</i> , 2007, 157, 810-811.	1.5	23
48	Treatment of Psoriasis Vulgaris with Calcipotriol Betamethasone Dipropionate Combination Followed by Calcipotriol and Assessment of the Adjuvant Basic Use of Urea-Based Emollients. <i>European Journal of Inflammation</i> , 2005, 3, 37-41.	0.5	11
49	Nonhealing Neck Ulcers. <i>Archives of Dermatology</i> , 1998, 134, 365.	1.4	2
50	Verrucous Nodule of the Finger. <i>Archives of Dermatology</i> , 1998, 134, 365-a-370.	1.4	13